|
Glioma – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 285 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Glioma - Pipeline Review, H1 2012', provides an overview of the Glioma therapeutic pipeline. This report provides information on the therapeutic development for.....
Introduction Global Markets Direct’s, 'Glioma - Pipeline Review, H1 2012', provides an overview of the Glioma therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. 'Glioma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Glioma. - A review of the Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glioma pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Glioma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Glioma pipeline depth and focus of Glioma therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Glioma Overview 12 Therapeutics Development 13 An Overview of Pipeline Products for Glioma 13 Glioma Therapeutics under Development by Companies 15 Glioma Therapeutics under Investigation by Universities/Institutes 23 Late Stage Products 33 Comparative Analysis 33 Mid Clinical Stage Products 34 Comparative Analysis 34 Early Clinical Stage Products 35 Comparative Analysis 35 Discovery and Pre-Clinical Stage Products 36 Comparative Analysis 36 Glioma Therapeutics – Products under Development by Companies 37 Glioma Therapeutics – Products under Investigation by Universities/Institutes 47 Companies Involved in Glioma Therapeutics Development 73 Bristol-Myers Squibb Company 73 Boehringer Ingelheim GmbH 74 F. Hoffmann-La Roche Ltd. 75 Amgen Inc. 76 Sanofi-Aventis 77 AstraZeneca PLC 78 Eli Lilly and Company 79 Viralytics Ltd. 80 GlaxoSmithKline plc 81 Antigenics, Inc. 82 Daiichi Sankyo Company, Ltd 83 Merck & Co., Inc. 84 Lentigen Corporation 85 Sangamo BioSciences, Inc. 86 YM BioSciences Inc. 87 Light Sciences Oncology, Inc. 88 Ark Therapeutics Group plc 89 Millennium Pharmaceuticals, Inc. 90 Novartis AG 91 ImClone Systems Incorporated 92 Actelion Ltd 93 Eisai Co., Ltd. 94 Nippon Shinyaku Co., Ltd. 95 OSI Pharmaceuticals, Inc. 96 Pfizer Inc. 97 Cell Therapeutics, Inc. 98 Exelixis, Inc. 99 Aduro BioTech 100 Geron Corporation 101 Merck KGaA 102 Access Pharmaceuticals, Inc. 103 EntreMed, Inc. 104 Celldex Therapeutics, Inc. 105 ImmunoCellular Therapeutics, Ltd. 106 Lixte Biotechnology Holdings, Inc. 107 Northwest Biotherapeutics, Inc. 108 Circadian Technologies Limited 109 Oncolytics Biotech Inc. 110 Oncothyreon Inc 111 Peregrine Pharmaceuticals, Inc. 112 Telik, Inc. 113 Oncogenex Pharmaceuticals, Inc. 114 Pharmacyclics, Inc. 115 PhytoMedical Technologies, Inc. 116 Transgene SA 117 Threshold Pharmaceuticals, Inc. 118 Natco Pharma Limited 119 Bradmer Pharmaceuticals Inc. 120 Proximagen Neuroscience plc. 121 Protox Therapeutics Inc. 122 e-Therapeutics plc 123 Rexahn Pharmaceuticals, Inc. 124 Antisense Pharma GmbH 125 INSYS Therapeutics, Inc. 126 Ambit Biosciences Corporation 127 Immupharma Plc 128 immatics biotechnologies GmbH 129 Advantagene, Inc. 130 Apogenix GmbH 131 Indena S.p.A. 132 Ascenta Therapeutics, Inc. 133 Oncolin Therapeutics, Inc. 134 Hawthorn Pharmaceuticals, Inc. 135 Diffusion Pharmaceuticals LLC 136 Arno Therapeutics, Inc. 137 Reata Pharmaceuticals, Inc. 138 Vascular Biogenics Ltd. 139 Burzynski Research Institute, Inc. 140 Stemline Therapeutics, Inc. 141 BioCancell Therapeutics, Inc. 142 Axelar AB 143 Advenchen Laboratories, LLC 144 Biotica Technology Ltd 145 Myriad Pharmaceuticals, Inc. 146 NOXXON Pharma AG 147 BiPar Sciences, Inc. 148 ChemoCentryx, Inc. 149 TVAX Biomedical, LLC 150 Sirnaomics, Inc. 151 to-BBB technologies BV 152 Lipopharma 153 AVEO Pharmaceuticals, Inc. 154 Nexgenix Pharmaceuticals, LLC 155 Archer Biosciences, Inc 156 Direct Therapeutics, Inc. 157 R&D Systems, Inc. 158 VectorLogics, Inc. 159 Eurofarma 160 TAU Therapeutics, LLC 161 Tocagen Inc 162 CytomX, LLC. 163 Glioma – Therapeutics Assessment 164 Assessment by Monotherapy Products 164 Assessment by Combination Products 165 Assessment by Route of Administration 166 Assessment by Molecule Type 169 Drug Profiles 172 Enzastaurin - Drug Profile 172 Recentin - Drug Profile 174 Rindopepimut - Drug Profile 175 Avastin - Drug Profile 176 Cilengitide - Drug Profile 178 Antineoplaston Therapy + Radiation Therapy - Drug Profile 180 IL13-PE38QQR - Drug Profile 182 Trabedersen - Drug Profile 184 Cerepro - Drug Profile 186 Recentin + Lomustine - Drug Profile 188 Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 189 Temozolomide - Drug Profile 192 Temozolomide + Etoposide - Drug Profile 193 Temozolomide + Radiation Therapy - Drug Profile 194 Temozolomide + Radiation Therapy - Drug Profile 196 Cilengitide + Temozolomide + Radiotherapy - Drug Profile 197 Avastin + Temozolomide + Radiation Therapy - Drug Profile 199 Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile 201 Temozolomide + Radiation Therapy - Drug Profile 203 Temozolomide + Radiation Therapy - Drug Profile 205 Lomustine + Radiation Therapy - Drug Profile 206 Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile 208 O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 210 Theracim + Radiation Therapy - Drug Profile 212 Temozolomide - Drug Profile 215 Temozolomide - Drug Profile 216 Temozolomide + Radiation Therapy - Drug Profile 217 Temozolomide + Lomustine - Drug Profile 218 Nimotuzumab + Temozolomide + Radiation Therapy - Drug Profile 219 Radiation Therapy + Procarbazine + ACNU - Drug Profile 221 Radiation Therapy + ACNU - Drug Profile 222 Temozolomide + Etoposide + Trofosfamid - Drug Profile 223 Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile 225 Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 227 Temozolomide - Drug Profile 229 Vorinostat + Bevacizumab + Radition Therapy - Drug Profile 230 Bevacizumab + Radiation Therapy - Drug Profile 232 Temozolomide - Drug Profile 233 Temodal + Radiation Therapy - Drug Profile 234 Temozolomide - Drug Profile 235 Atengenal + Astugenal - Drug Profile 236 Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate + Radiation Therapy - Drug Profile 238 Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile 240 Glioma Therapeutics – Drug Profile Updates 242 Glioma Therapeutics – Discontinued Products 246 Glioma Therapeutics - Dormant Products 250 Glioma – Product Development Milestones 271 Featured News & Press Releases 271 Appendix 281 Methodology 281 Expert Panel Validation 282 Contact Us 282 Disclaimer 282 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Glioma, H1 2012 16 Products under Development for Glioma – Comparative Analysis, H1 2012 17 Number of Products under Development by Companies, H1 2012 19 Number of Products under Development by Companies, H1 2012 (Contd..1) 20 Number of Products under Development by Companies, H1 2012 (Contd..2) 21 Number of Products under Development by Companies, H1 2012 (Contd..3) 22 Number of Products under Development by Companies, H1 2012 (Contd..4) 23 Number of Products under Development by Companies, H1 2012 (Contd..5) 24 Number of Products under Development by Companies, H1 2012 (Contd..6) 25 Number of Products under Investigation by Universities/Institutes, H1 2012 27 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 28 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 29 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 30 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 31 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 32 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 33 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 34 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 35 Comparative Analysis by Late Stage Development, H1 2012 36 Comparative Analysis by Mid Clinical Stage Development, H1 2012 37 Comparative Analysis by Early Clinical Stage Development, H1 2012 38 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 39 Products under Development by Companies, H1 2012 40 Products under Development by Companies, H1 2012 (Contd..1) 41 Products under Development by Companies, H1 2012 (Contd..2) 42 Products under Development by Companies, H1 2012 (Contd..3) 43 Products under Development by Companies, H1 2012 (Contd..4) 44 Products under Development by Companies, H1 2012 (Contd..5) 45 Products under Development by Companies, H1 2012 (Contd..6) 46 Products under Development by Companies, H1 2012 (Contd..7) 47 Products under Development by Companies, H1 2012 (Contd..8) 48 Products under Development by Companies, H1 2012 (Contd..9) 49 Products under Investigation by Universities/Institutes, H1 2012 50 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 51 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 52 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 53 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 54 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 55 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 56 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 57 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 58 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 59 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 60 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 61 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 62 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 63 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 64 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 65 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 66 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 67 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 68 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 69 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 70 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 71 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 72 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 73 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 74 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 75 Bristol-Myers Squibb Company, H1 2012 76 Boehringer Ingelheim GmbH, H1 2012 77 F. Hoffmann-La Roche Ltd., H1 2012 78 Amgen Inc., H1 2012 79 Sanofi-Aventis, H1 2012 80 AstraZeneca PLC, H1 2012 81 Eli Lilly and Company, H1 2012 82 Viralytics Ltd., H1 2012 83 GlaxoSmithKline plc, H1 2012 84 Antigenics, Inc., H1 2012 85 Daiichi Sankyo Company, Ltd, H1 2012 86 Merck & Co., Inc., H1 2012 87 Lentigen Corporation, H1 2012 88 Sangamo BioSciences, Inc., H1 2012 89 YM BioSciences Inc., H1 2012 90 Light Sciences Oncology, Inc., H1 2012 91 Ark Therapeutics Group plc, H1 2012 92 Millennium Pharmaceuticals, Inc., H1 2012 93 Novartis AG, H1 2012 94 ImClone Systems Incorporated, H1 2012 95 Actelion Ltd, H1 2012 96 Eisai Co., Ltd., H1 2012 97 Nippon Shinyaku Co., Ltd., H1 2012 98 OSI Pharmaceuticals, Inc., H1 2012 99 Pfizer Inc., H1 2012 100 Cell Therapeutics, Inc., H1 2012 101 Exelixis, Inc., H1 2012 102 Aduro BioTech, H1 2012 103 Geron Corporation, H1 2012 104 Merck KGaA, H1 2012 105 Access Pharmaceuticals, Inc., H1 2012 106 EntreMed, Inc., H1 2012 107 Celldex Therapeutics, Inc., H1 2012 108 ImmunoCellular Therapeutics, Ltd., H1 2012 109 Lixte Biotechnology Holdings, Inc., H1 2012 110 Northwest Biotherapeutics, Inc., H1 2012 111 Circadian Technologies Limited, H1 2012 112 Oncolytics Biotech Inc., H1 2012 113 Oncothyreon Inc, H1 2012 114 Peregrine Pharmaceuticals, Inc., H1 2012 115 Telik, Inc., H1 2012 116 Oncogenex Pharmaceuticals, Inc., H1 2012 117 Pharmacyclics, Inc., H1 2012 118 PhytoMedical Technologies, Inc., H1 2012 119 Transgene SA, H1 2012 120 Threshold Pharmaceuticals, Inc., H1 2012 121 Natco Pharma Limited, H1 2012 122 Bradmer Pharmaceuticals Inc., H1 2012 123 Proximagen Neuroscience plc., H1 2012 124 Protox Therapeutics Inc., H1 2012 125 e-Therapeutics plc, H1 2012 126 Rexahn Pharmaceuticals, Inc., H1 2012 127 Antisense Pharma GmbH, H1 2012 128 INSYS Therapeutics, Inc., H1 2012 129 Ambit Biosciences Corporation, H1 2012 130 Immupharma Plc, H1 2012 131 immatics biotechnologies GmbH, H1 2012 132 Advantagene, Inc., H1 2012 133 Apogenix GmbH, H1 2012 134 Indena S.p.A., H1 2012 135 Ascenta Therapeutics, Inc., H1 2012 136 Oncolin Therapeutics, Inc., H1 2012 137 Hawthorn Pharmaceuticals, Inc., H1 2012 138 Diffusion Pharmaceuticals LLC, H1 2012 139 Arno Therapeutics, Inc., H1 2012 140 Reata Pharmaceuticals, Inc., H1 2012 141 Vascular Biogenics Ltd., H1 2012 142 Burzynski Research Institute, Inc., H1 2012 143 Stemline Therapeutics, Inc., H1 2012 144 BioCancell Therapeutics, Inc., H1 2012 145 Axelar AB, H1 2012 146 Advenchen Laboratories, LLC, H1 2012 147 Biotica Technology Ltd, H1 2012 148 Myriad Pharmaceuticals, Inc., H1 2012 149 NOXXON Pharma AG, H1 2012 150 BiPar Sciences, Inc., H1 2012 151 ChemoCentryx, Inc., H1 2012 152 TVAX Biomedical, LLC, H1 2012 153 Sirnaomics, Inc., H1 2012 154 to-BBB technologies BV, H1 2012 155 Lipopharma, H1 2012 156 AVEO Pharmaceuticals, Inc., H1 2012 157 Nexgenix Pharmaceuticals, LLC, H1 2012 158 Archer Biosciences, Inc, H1 2012 159 Direct Therapeutics, Inc., H1 2012 160 R&D Systems, Inc., H1 2012 161 VectorLogics, Inc., H1 2012 162 Eurofarma, H1 2012 163 TAU Therapeutics, LLC, H1 2012 164 Tocagen Inc, H1 2012 165 CytomX, LLC., H1 2012 166 Assessment by Monotherapy Products, H1 2012 167 Assessment by Combination Products, H1 2012 168 Assessment by Stage and Route of Administration, H1 2012 171 Assessment by Molecule Type, H1 2012 174 Glioma Therapeutics – Drug Profile Updates 245 Glioma Therapeutics – Discontinued Products 249 Glioma Therapeutics – Discontinued Products (Contd..1) 250 Glioma Therapeutics – Discontinued Products (Contd..2) 251 Glioma Therapeutics – Discontinued Products (Contd..3) 252 Glioma Therapeutics – Dormant Products 253 Glioma Therapeutics – Dormant Products (Contd..1) 254 Glioma Therapeutics – Dormant Products (Contd..2) 255 Glioma Therapeutics – Dormant Products (Contd..3) 256 Glioma Therapeutics – Dormant Products (Contd..4) 257 Glioma Therapeutics – Dormant Products (Contd..5) 258 Glioma Therapeutics – Dormant Products (Contd..6) 259 Glioma Therapeutics – Dormant Products (Contd..7) 260 Glioma Therapeutics – Dormant Products (Contd..8) 261 Glioma Therapeutics – Dormant Products (Contd..9) 262 Glioma Therapeutics – Dormant Products (Contd..10) 263 Glioma Therapeutics – Dormant Products (Contd..11) 264 Glioma Therapeutics – Dormant Products (Contd..12) 265 Glioma Therapeutics – Dormant Products (Contd..13) 266 Glioma Therapeutics – Dormant Products (Contd..14) 267 Glioma Therapeutics – Dormant Products (Contd..15) 268 Glioma Therapeutics – Dormant Products (Contd..16) 269 Glioma Therapeutics – Dormant Products (Contd..17) 270 Glioma Therapeutics – Dormant Products (Contd..18) 271 Glioma Therapeutics – Dormant Products (Contd..19) 272 Glioma Therapeutics – Dormant Products (Contd..20) 273 List of Figures Number of Products under Development for Glioma, H1 2012 16 Products under Development for Glioma – Comparative Analysis, H1 2012 17 Products under Development by Companies, H1 2012 18 Products under Investigation by Universities/Institutes, H1 2012 26 Late Stage Products, H1 2012 36 Mid Clinical Stage Products, H1 2012 37 Early Clinical Stage Products, H1 2012 38 Discovery and Pre-Clinical Stage Products, H1 2012 39 Assessment by Monotherapy Products, H1 2012 167 Assessment by Combination Products, H1 2012 168 Assessment by Route of Administration, H1 2012 169 Assessment by Stage and Route of Administration, H1 2012 170 Assessment by Molecule Type, H1 2012 172 Assessment by Stage and Molecule Type, H1 2012 173 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
